Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060772 · ClinicalTrials.gov registry record · Phase 2
A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT03060772 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 50 participants.
The verdict
NCT03060772, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study is a single center, open-label, randomized clinical trial to determine the effect of pioglitazone (PIO) treatment on alveolar macrophage immune function, redox stress, and NADPH oxidase expression in outpatient alcoholic subjects. The researchers will recruit a cohort of otherwise healthy patients with an alcoholic use disorder from the Substance Abuse Treatment Program at the Atlanta Veterans Affairs (VA) Medical Center and randomize them to receive the usual treatment for two to four weeks or to the usual treatment plus PIO treatment for two to four weeks. There will also be a healthy control group (matched on age, gender, and smoking status) that will receive no treatment. To measure the effect of pioglitazone, participants will undergo a bronchoscopy before taking the study drug and then again 2-4 weeks later to look for changes. The bronchoscopy will allow researchers to obtain fluid from the lungs to see how well their immune cells respond to bacteria by determining phagocytic capacity.
Interventions
- DRUG Pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2020-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03060772
The ClinicalTrials.gov registry entry for NCT03060772 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pioglitazone is the first listed.
NCT03060772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03060772 about?
NCT03060772 is a clinical study titled "A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)". This study is a single center, open-label, randomized clinical trial to determine the effect of pioglitazone (PIO) treatment on alveolar macrophage immune function, redox stress, and NADPH oxidase expression in outpatient alcoholic subjects. The researchers will recruit a cohort of otherwise healthy...
What is the current status of trial NCT03060772?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2018-01-03. Estimated completion is 2020-01-28.
What interventions are being tested in trial NCT03060772?
The interventions under investigation include: Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT03060772?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.